Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

Abstract

Treatment with anti-TNF alpha was safe and well tolerated and resulted in significant clinical and laboratory improvements. These preliminary results support the hypothesis that TNF alpha is an important regulator in RA, and suggest that it may be a useful new therapeutic target in this disease.